List of Dexycu Kit drug patents

Dexycu Kit is owned by Eyepoint Pharms.

Dexycu Kit contains Dexamethasone.

Dexycu Kit has a total of 7 drug patents out of which 1 drug patent has expired.

Expired drug patents of Dexycu Kit are:

  • US7560120

Dexycu Kit was authorised for market use on 09 February, 2018.

Dexycu Kit is available in suspension;intraocular dosage forms.

Dexycu Kit can be used as a method of loading medication into a syringe and delivering the medication to a treatment site, treatment of postoperative inflammation.

The generics of Dexycu Kit are possible to be released after 23 June, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560120 EYEPOINT PHARMS Vehicles for delivery of biologically active substances
Sep, 2022

(4 months ago)

US6960346 EYEPOINT PHARMS Vehicles for delivery of biologically active substances
Jul, 2023

(4 months from now)

US10799642 EYEPOINT PHARMS Dose guides for injection syringe
May, 2032

(9 years from now)

US10028965 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(11 years from now)

US10159683 EYEPOINT PHARMS Use of sustained release dexamethasone in post-cataract surgery inflammation
May, 2034

(11 years from now)

US10022502 EYEPOINT PHARMS Dose guides for injection syringe
Jun, 2034

(11 years from now)

US11097061 EYEPOINT PHARMS Systems, kits and methods for loading and delivering a small volume dose from a syringe
Jun, 2039

(16 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic